Southern California Research Center, Coronado, CA 92118, USA.
Southern California Research Center, Coronado, CA 92118, USA; University of California, San Diego School of Medicine, San Diego, CA, USA.
Clin Liver Dis. 2016 Nov;20(4):681-692. doi: 10.1016/j.cld.2016.07.002.
The goal in patients with immune active hepatitis B virus (HBV) infection is to significantly suppress viral replication and prevent progression of fibrosis to cirrhosis and liver decompensation and decrease the incidence of hepatocellular carcinoma. This is achievable by the highly active antivirals, entecavir and tenofovir, which are considered first-line therapy in most patients with immune active hepatitis C virus and after liver transplantation to prevent HBV recurrence. Patients with decompensated cirrhosis should be referred for liver transplantation and treated with first-line antivirals as early as possible, with the goal of achieving complete viral suppression in the shortest time possible.
对于免疫激活的乙型肝炎病毒 (HBV) 感染患者，其治疗目标是显著抑制病毒复制，预防纤维化进展为肝硬化和肝功能失代偿，减少肝细胞癌的发生。恩替卡韦和替诺福韦等高效抗病毒药物可以实现这一目标，在大多数免疫激活的丙型肝炎病毒患者中以及肝移植后，这些药物被认为是预防 HBV 复发的一线治疗药物。对于失代偿性肝硬化患者，应进行肝移植，并尽早使用一线抗病毒药物进行治疗，目标是在最短的时间内实现完全病毒抑制。
